Manas AI Secures $26M Seed Extension, Bolstering AI Drug Discovery
September 26, 2025, 10:03 pm
Manas AI, a leader in AI-driven drug discovery, announced a $26 million seed extension. This capital accelerates its mission. The company develops faster, more precise, and cost-efficient medicines. Ujjwal Singh now serves as Co-Founder and Chief Technology Officer. His extensive background in AI and product leadership is vital. The new funds will advance Manas AI's foundational drug discovery models. They will also progress existing therapeutic campaigns. This investment strengthens their interdisciplinary team. It builds on a previous $24.6 million seed round. Top venture firms back this pharmaceutical revolution. Manas AI leverages neuro-symbolic, science-based AI. It seeks to bring transformative treatments to market. This move signals a new era for medicine.
Manas AI today announced a significant funding milestone. The NYC-based company closed a $26 million Seed Extension round. This capital infusion accelerates its groundbreaking work. Manas AI aims to revolutionize drug discovery and development. Artificial intelligence drives its core mission.
The pharmaceutical industry faces immense challenges. Traditional drug development is slow and expensive. It often yields inefficient outcomes. Manas AI tackles these issues head-on. It integrates cutting-edge biomedical expertise. Advanced AI capabilities power its platform. This fusion creates a new path forward. Manas AI develops medications faster. It reduces costs significantly. Its therapies offer greater precision. This approach reshapes pharmaceutical innovation.
New leadership joins the Manas AI team. Ujjwal Singh takes on a dual role. He becomes Co-Founder and Chief Technology Officer. Singh brings a wealth of experience. His expertise will guide technological expansion. This appointment strengthens Manas AI's leadership.
The newly secured capital has clear objectives. A primary focus lies on foundational models. Funds will accelerate their development. These models are central to Manas AI’s technology. The investment also supports existing therapeutic campaigns. It propels promising new treatments closer to reality. Manas AI plans team expansion. It seeks top talent across disciplines. Ujjwal Singh’s expertise will shape this growth. He builds out the company’s technological capabilities.
Ujjwal Singh boasts an impressive career. His track record includes leadership and innovation. Most recently, he led Multiverse. He served as Chief Technology and Product Officer. There, he drove product strategy and tech development. Before Multiverse, he was Head of Workplace at Meta. This role showcased his ability to lead large initiatives. Singh also enjoyed a significant tenure at Google. He spearheaded numerous product innovations. At Google, he partnered in Area 120. This internal incubator fostered experimental products. As Senior Director of Engineering, he founded Google Hangouts. He successfully launched the communication platform. Singh also expanded YouTube. He spearheaded engineering efforts for YouTube Kids. He developed YouTube Music and YouTube Gaming. His career demonstrates immense scaling capability.
This Seed Extension builds on prior success. An earlier $24.6 million Seed Round concluded in January. General Catalyst and Reid Hoffman notably led that round. The current seed extension saw broad investor participation. Major firms invested. These include The General Partnership, Wisdom Ventures, and Blitzscaling Ventures. Westbound Equity Partners and Mosaic Ventures also joined. Several individual investors recognized Manas AI’s potential. Their confidence underscores the company’s innovative approach.
Manas AI leverages sophisticated models. It builds neuro-symbolic, science-based foundational models. These drive its discovery process. The goal is to bring transformative medicines to market. This precision approach targets diseases more effectively. It minimizes side effects. It optimizes patient outcomes. The company is at the forefront of AI drug discovery. It pioneers a new era of healthcare technology.
Dr. Siddhartha Mukherjee co-founded Manas AI. He serves as CEO. His vision guides the company. The mission is clear: accelerate discovery. Deliver highly targeted therapies. This resonates deeply with investors and leaders. The team believes in harnessing AI revolution. They deploy its most impactful aspects. This creates meaningful change in medicine.
The integration of AI into drug development is transformative. It promises to shorten timelines. It can drastically reduce costs. AI models analyze vast datasets. They predict molecular interactions. They identify promising drug candidates faster. This efficiency accelerates research and development. It allows for more trials. It brings more treatments to patients. Manas AI exemplifies this paradigm shift.
Manas AI’s work is vital. It addresses unmet medical needs. It targets diseases that lack effective treatments. Its platform identifies novel biological pathways. It designs therapeutic molecules with precision. This leads to breakthroughs. These breakthroughs have global impact. They improve human health. They extend lifespans.
The future of medicine looks different. It will be faster, smarter, and more personal. Manas AI stands at this forefront. Its continued funding ensures progress. Its expanded leadership strengthens its position. The company moves rapidly. It shapes the next generation of pharmaceuticals. This is not just about new drugs. It is about a new way to heal. It is about innovation at speed.
Manas AI today announced a significant funding milestone. The NYC-based company closed a $26 million Seed Extension round. This capital infusion accelerates its groundbreaking work. Manas AI aims to revolutionize drug discovery and development. Artificial intelligence drives its core mission.
The pharmaceutical industry faces immense challenges. Traditional drug development is slow and expensive. It often yields inefficient outcomes. Manas AI tackles these issues head-on. It integrates cutting-edge biomedical expertise. Advanced AI capabilities power its platform. This fusion creates a new path forward. Manas AI develops medications faster. It reduces costs significantly. Its therapies offer greater precision. This approach reshapes pharmaceutical innovation.
New leadership joins the Manas AI team. Ujjwal Singh takes on a dual role. He becomes Co-Founder and Chief Technology Officer. Singh brings a wealth of experience. His expertise will guide technological expansion. This appointment strengthens Manas AI's leadership.
The newly secured capital has clear objectives. A primary focus lies on foundational models. Funds will accelerate their development. These models are central to Manas AI’s technology. The investment also supports existing therapeutic campaigns. It propels promising new treatments closer to reality. Manas AI plans team expansion. It seeks top talent across disciplines. Ujjwal Singh’s expertise will shape this growth. He builds out the company’s technological capabilities.
Ujjwal Singh boasts an impressive career. His track record includes leadership and innovation. Most recently, he led Multiverse. He served as Chief Technology and Product Officer. There, he drove product strategy and tech development. Before Multiverse, he was Head of Workplace at Meta. This role showcased his ability to lead large initiatives. Singh also enjoyed a significant tenure at Google. He spearheaded numerous product innovations. At Google, he partnered in Area 120. This internal incubator fostered experimental products. As Senior Director of Engineering, he founded Google Hangouts. He successfully launched the communication platform. Singh also expanded YouTube. He spearheaded engineering efforts for YouTube Kids. He developed YouTube Music and YouTube Gaming. His career demonstrates immense scaling capability.
This Seed Extension builds on prior success. An earlier $24.6 million Seed Round concluded in January. General Catalyst and Reid Hoffman notably led that round. The current seed extension saw broad investor participation. Major firms invested. These include The General Partnership, Wisdom Ventures, and Blitzscaling Ventures. Westbound Equity Partners and Mosaic Ventures also joined. Several individual investors recognized Manas AI’s potential. Their confidence underscores the company’s innovative approach.
Manas AI leverages sophisticated models. It builds neuro-symbolic, science-based foundational models. These drive its discovery process. The goal is to bring transformative medicines to market. This precision approach targets diseases more effectively. It minimizes side effects. It optimizes patient outcomes. The company is at the forefront of AI drug discovery. It pioneers a new era of healthcare technology.
Dr. Siddhartha Mukherjee co-founded Manas AI. He serves as CEO. His vision guides the company. The mission is clear: accelerate discovery. Deliver highly targeted therapies. This resonates deeply with investors and leaders. The team believes in harnessing AI revolution. They deploy its most impactful aspects. This creates meaningful change in medicine.
The integration of AI into drug development is transformative. It promises to shorten timelines. It can drastically reduce costs. AI models analyze vast datasets. They predict molecular interactions. They identify promising drug candidates faster. This efficiency accelerates research and development. It allows for more trials. It brings more treatments to patients. Manas AI exemplifies this paradigm shift.
Manas AI’s work is vital. It addresses unmet medical needs. It targets diseases that lack effective treatments. Its platform identifies novel biological pathways. It designs therapeutic molecules with precision. This leads to breakthroughs. These breakthroughs have global impact. They improve human health. They extend lifespans.
The future of medicine looks different. It will be faster, smarter, and more personal. Manas AI stands at this forefront. Its continued funding ensures progress. Its expanded leadership strengthens its position. The company moves rapidly. It shapes the next generation of pharmaceuticals. This is not just about new drugs. It is about a new way to heal. It is about innovation at speed.